Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis
Background: Efanesoctocog alfa is a first-in-class high-sustained factor VIII (FVIII) replacement therapy. In the phase III XTEND-1 (NCT04161495) study, once-weekly efanesoctocog alfa prophylaxis (50 IU/kg) was well-tolerated and achieved high-sustained factor levels in the normal to near-normal ran...
Gardado en:
| Principais autores: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publishing
2026-01-01
|
| Series: | Therapeutic Advances in Hematology |
| Acceso en liña: | https://doi.org/10.1177/20406207251398986 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|